ContraVir Pharmaceuticals Inc (CTRV) Short Interest Update
ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 1,489,600 shares, a growth of 32.9% from the August 31st total of 1,120,456 shares. Currently, 5.5% of the shares of the stock are sold short. Based on an average trading volume of 145,019 shares, the days-to-cover ratio is presently 10.3 days.
Separately, Maxim Group reaffirmed a “buy” rating on shares of ContraVir Pharmaceuticals in a research note on Wednesday, June 15th.
Shares of ContraVir Pharmaceuticals (NASDAQ:CTRV) opened at 1.10 on Wednesday. The firm’s 50-day moving average is $1.12 and its 200 day moving average is $1.06. ContraVir Pharmaceuticals has a 52 week low of $0.76 and a 52 week high of $3.39. The firm’s market cap is $59.02 million.
Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in ContraVir Pharmaceuticals by 8.7% in the second quarter. Vanguard Group Inc. now owns 915,369 shares of the biopharmaceutical company’s stock valued at $952,000 after buying an additional 73,135 shares during the period. Teachers Advisors Inc. boosted its stake in ContraVir Pharmaceuticals by 95.2% in the second quarter. Teachers Advisors Inc. now owns 289,919 shares of the biopharmaceutical company’s stock valued at $1,102,000 after buying an additional 141,368 shares during the period. Finally, Prospera Financial Services Inc boosted its stake in ContraVir Pharmaceuticals by 0.6% in the second quarter. Prospera Financial Services Inc now owns 178,550 shares of the biopharmaceutical company’s stock valued at $186,000 after buying an additional 1,000 shares during the period.
About ContraVir Pharmaceuticals
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of virology drugs to treat diseases of unmet needs, such as herpes zoster and hepatitis B (HBV). It is developing targeted antiviral therapies with over two drug candidates in clinical studies. Its FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743 that it is developing for the treatment of herpes zoster, which is an infection caused by the reactivation of varicella zoster virus or VZV.
Receive News & Stock Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.